The opioid epidemic is one of the deadliest problems facing the U.S. today. Through the development of new pain management devices, medtech could be a leader in solving the crisis. The prescription opioid overdose crisis in America didn’t start until the late 1990s, when pharmaceutical companies touted prescription painkillers that weren’t supposed to be addictive. […]
Nevro Corp.
Nevro wins FDA nod for next-gen Senza II SCS
Nevro Corp. (NYSE:NVRO) said yesterday it won FDA approval for its next-generation Senza II spinal cord stimulation system. The Redwood City, Calif.-based company said the Senza II SCS system is designed to deliver HF10 therapy through a smaller footprint while maintaining the durability and performance of the current generation device. Both the next-gen device and previous versions […]
7 medical devices combating the opioid crisis
Opioid-related deaths have become an epidemic in the U.S., garnering attention from the White House, the FDA and many other governmental bodies. From 2000 to 2014, nearly half a million Americans died from drug overdoses. In 2015, more than 50,000 people died from drug overdoses, and 33,000 were opioid-related. Prescription overdoses continue to cause more […]
Nevro wins CE Mark for Senza II spinal cord stim device
Nevro Corp. (NYSE:NVRO) said yesterday that it won CE Mark approval in the European Union for the next generation of its spinal cord stimulator for treating chronic pain. Redwood City, Calif-based Nevro said its Senza II SCS is smaller than its predecessor Senza device, which won an FDA nod in May 2015. Both devices are designed to deliver high-frequency electrical […]
Nevro wins MR-conditional CE Mark for Senza spinal cord stim
Nevro Corp. (NYSE:NVRO) yesterday said it won MR-conditional CE Mark approval in the European Union for its Senza spinal cord stimulator for treating chronic pain. The retroactive approval applies to all patients implanted with the Senza device, which was previously CE Marked for head and extremity MRI scans, according to the Redwood City, Calif.-based company. Senza, […]
Nevro shares fall as Q3 losses rise
Shares in Nevro (NYSE:NVRO) fell today after the medical device maker posted third quarter earnings that saw losses grow over 50%. The Redwood City, Calif.-based company posted losses of $6.2 million, or 21¢ per share, on sales of $82.3 million for the 3 months ended September 30, seeing losses grow 60.3% while sales grew 35% compared […]
Judge: Nevro lawyer’s tactic ‘sleazy’ but legal in BSX patent spat
A federal judge in California found this week that although Nevro Corp.‘s (NYSE:NVRO) failure to correct a patent examiner’s misunderstanding of prior art was a little “sleazy,” it does not account to inequitable conduct. Boston Scientific (NYSE:BSX) argued that the prosecuting attorney had a duty to respond to the examiner’s confusion, which came about as part […]
Nevro ticks down despite Q2 sales beat
Nevro (NYSE:NVRO) shares ticked down yesterday despite second-quarter revenues that came in well ahead of analysts’ expectations and just beat the company’s own forecast. Redwood City, Calif.-based Nevro posted losses of -$11.5 million, or -40¢ per share, on sales of $78.02 million for the 3 months ended June 30, widening its losses by 32.9% on sales […]
Halyard Health taps former Acelity head Woody for CEO | Personnel Moves July 5, 2017
Halyard Health (NYSE:HYH) said late last month it tapped former Acelity prez & CEO Joseph Woody as its new chief executive officer, replacing a retiring Robert Abernathy. Woody will also assume a seat on the board of directors, with former CEO Abernathy continuing on as board chair, the Alpharetta, Ga.-based company said. “On behalf of the […]
Nevro gains on fiscal Q2 prelims
Nevro Corp. (NYSE:NVRO) shares gained today in pre-market trading after the neuromodulation company reported preliminary sales numbers for its fiscal second quarter. Redwood City, Calif.-based Nevro said it expects to post revenues of $77.5 million to $78.0 million for the three months ended June 30, which would be a 39.9% to 40.8% increase over the $55.4 million […]
‘Growing pains’ push Nevro shares down on Q1 sales, earnings misses
Nevro (NYSE:NVRO) shares were under pressure in pre-market trading today after the medical device maker missed expectations for its 1st-quarter sales and earnings. Redwood City, Calif.-based Nevro, which makes the Senza spinal cord stimulation device, posted losses of -$14.7 million, or -50¢ per share, on sales of $68.4 million for the 3 months ended March 31. That […]